Citius Oncology CTOR Cash Flow Statement (2023-2026)

NASDAQ CTOR
$0.94 +0.01 (+1.17%)
As of: Sep 9, 2026 · 3:59 PM EDT
Reported Financials

Citius Oncology Quarterly Cash Flow Statement

Periods 14 quarters
Latest Jun 2026

Citius Oncology reported cash from operations of -$2.71M and free cash flow of -$2.71M for the quarter ended Jun 2026. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -0.15M-0.20M-0.77M-4.73M-9.56M-14.34M-6.66M-7.74M-5.37M-5.00M-5.53M-26.61M-8.92M
Share-based Compensation 12.60M1.92M3.87M5.83M12.75M18.50M18.50M18.17M2.30M18.10M18.10M18.10M
Deferred Taxes 0.14M0.29M0.43M0.26M0.26M0.26M0.26M0.26M-0.23M-0.11M
Cash from Operations -0.17M-0.10M-0.38M-0.19M-0.37M-7.35M-3.83M-2.71M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges 0.18M
Change in Working Capital
Change in Receivables 4.05M-2.97M-0.39M
Change in Inventory 6.11M0.96M1.87M3.71M0.35M0.02M-0.03M
Change in Account Payables -1.08M7.62M11.45M2.31M2.05M2.52M2.65M-2.79M-1.56M-1.57M
Change in Accured Expenses 0.02M0.07M0.36M-0.20M-0.26M0.19M6.23M2.49M-0.26M-4.37M0.43M19.54M0.02M
Investing Activities
Cash from Investing Activities -0.66M24.74M0.07M-4.40M-0.60M-2.00M
Financing Activities
Other financing activities 9.56M
Debt Issuance and Repayment
Long-Term Debt Issuances 0.78M0.20M0.33M
Change in Capital Stock
Net Shares Issued and Repurchased 0.15M5.75M5.75M
Net Equity Issued and Repurchased 15.17M15.13M-0.06M-818.00
Misc.
Cash from Financing Activities 0.78M-24.55M0.26M15.13M-0.23M18.64M
Change in Cash -0.17M0.25M-0.26M584.00-0.03M3.37M-4.66M13.93M
Free Cash Flow -0.17M-0.10M-0.38M-0.19M-0.37M-7.35M-3.83M-2.71M
Net Cash Flow -0.17M-0.10M-0.26M584.00-0.03M3.37M-4.66M13.93M